This notice in TED website: https://ted.europa.eu/udl?uri=TED:NOTICE:114370-2019:TEXT:EN:HTML

# United Kingdom-Runcorn: Pharmaceutical products 2019/S 050-114370

#### **Contract notice**

#### **Supplies**

## **Legal Basis:**

Directive 2014/24/EU

#### **Section I: Contracting authority**

## I.1) Name and addresses

NHS Commissioning Board (operating under the name of NHS England)

NHS England, Rutland House, 2nd Floor

Runcorn WA7 2ES

United Kingdom

E-mail: michelle.clarke6@nhs.net

NUTS code: UK Internet address(es):

Main address: https://nhsengland.bravosolution.co.uk

Address of the buyer profile: https://nhsengland.bravosolution.co.uk

#### 1.2) Information about joint procurement

The contract is awarded by a central purchasing body

## 1.3) Communication

The procurement documents are available for unrestricted and full direct access, free of charge, at: https://nhsengland.bravosolution.co.uk

Additional information can be obtained from the abovementioned address

Tenders or requests to participate must be submitted electronically via: https://nhsengland.bravosolution.co.uk Tenders or requests to participate must be submitted to the abovementioned address

## 1.4) Type of the contracting authority

Ministry or any other national or federal authority, including their regional or local subdivisions

#### 1.5) Main activity

Health

# Section II: Object

# II.1) Scope of the procurement

## II.1.1) Title:

NHS Framework for the NHS London Region, Branded Medicines – Tranche B, Cytokine Modulators and Other Monoclonal Antibodies and Antiretrovirals

Reference number: CM/PHR/16/5515

# II.1.2) Main CPV code

33600000

#### II.1.3) Type of contract

**Supplies** 

#### II.1.4) Short description:

CM/PHR/16/5515/01 — 1.9.2019 to 31.8.2021 – NHS Framework for the NHS London Region, Branded Medicines – Tranche B with an option to extend (at the Authority's discretion) for a period or periods up to a total of 24 months.

CM/PHR/16/5515/02 — 1.9.2019 to 31.8.2020 — NHS Framework for the NHS London Region, Branded Medicines – Annual Tranche — Cytokine Modulators and other monoclonal antibodies with an option to extend (at the Authority's discretion) for a period or periods up to a total of 12 months.

CM/PHR/16/5515/03 — 1.9.2019 to 31.8.2020 – NHS Framework for the NHS London Region, Branded Medicines — Antiretrovirals with an option to extend (at the Authority's discretion) for a period or periods up to a total of 12 months.

#### II.1.5) Estimated total value

Value excluding VAT: 702 212 438.00 GBP

#### II.1.6) Information about lots

This contract is divided into lots: yes Tenders may be submitted for all lots

#### II.2) Description

#### II.2.1) **Title:**

NHS Framework for the NHS London Region, Branded Medicines – Tranche B with an Option to Extend (at the Authority's Discretion) for a Period or Periods up to a Total of 24 Months

Lot No: 1

#### II.2.2) Additional CPV code(s)

33600000

#### II.2.3) Place of performance

NUTS code: UKI

Main site or place of performance:

Please refer to Schedule 8 of the Framework Agreement.

#### II.2.4) **Description of the procurement:**

CM/PHR/16/5515/01 — 1.9.2019 to 31.8.2021 – NHS Framework for the NHS London Region, Branded Medicines – Tranche B with an option to extend (at the Authority's discretion) for a period or periods up to a total of 24 months.

Products associated with the lots are listed on Document No. 05 of the Invitation to offer.

Each individual National product code (NPC) pack description in each of the regions (London) is deemed to be a separate product for the application of the award criteria.

There is no restriction on the number of products that bidders can offer for, or be awarded.

The Framework Agreement is intended for use by the Department of Health, Public Health England and the NHS in England.

The framework may also be used by private sector contractors and agents working on behalf of the above

# II.2.5) Award criteria

Price is not the only award criterion and all criteria are stated only in the procurement documents

#### II.2.6) Estimated value

#### II.2.7) Duration of the contract, framework agreement or dynamic purchasing system

Start: 01/09/2019

**TED** 

End: 31/08/2021

This contract is subject to renewal: no

#### II.2.10) Information about variants

Variants will be accepted: yes

#### II.2.11) Information about options

Options: no

#### II.2.12) Information about electronic catalogues

#### II.2.13) Information about European Union funds

The procurement is related to a project and/or programme financed by European Union funds: no

#### II.2.14) Additional information

#### II.2) Description

# II.2.1) **Title:**

NHS Framework for the NHS London Region, Branded Medicines – Annual Tranche — Cytokine Modulators and other Monoclonal Antibodies with an Option to Extend (at the Authority's discretion) for a Period Lot No: 2

### II.2.2) Additional CPV code(s)

33600000

#### II.2.3) Place of performance

NUTS code: UKI

Main site or place of performance:

Please refer to Schedule 8 of the Framework Agreement.

#### II.2.4) **Description of the procurement:**

CM/PHR/16/5515/02 — 1.9.2019 to 31.8.2020 — NHS Framework for the NHS London Region, Branded Medicines – annual tranche — Cytokine modulators and other monoclonal antibodies with an option to extend (at the Authority's discretion) for a period or periods up to a total of 12 months.

Products associated with the lots are listed on document No. 05 of the invitation to offer.

Each individual National Product code (NPC) pack description in each of the regions (London) is deemed to be a separate product for the application of the award criteria.

There is no restriction on the number of products that bidders can offer for, or be awarded.

The Framework Agreement is intended for use by the Department of Health, Public Health England and the NHS in England.

The framework may also be used by private sector contractors and agents working on behalf of the above.

# II.2.5) Award criteria

Price is not the only award criterion and all criteria are stated only in the procurement documents

#### II.2.6) Estimated value

# II.2.7) Duration of the contract, framework agreement or dynamic purchasing system

Start: 01/09/2019 End: 31/08/2020

This contract is subject to renewal: no

#### II.2.10) Information about variants

Variants will be accepted: yes

# II.2.11) Information about options

Options: no

#### II.2.12) Information about electronic catalogues

#### II.2.13) Information about European Union funds

The procurement is related to a project and/or programme financed by European Union funds: no

#### II.2.14) Additional information

#### II.2) Description

#### II.2.1) **Title:**

NHS Framework for the NHS London Region, Branded Medicines — Antiretrovirals with an Option to Extend (at the Authority's Discretion) for a Period or Periods up to a total of 12 months

Lot No: 3

#### II.2.2) Additional CPV code(s)

33600000

#### II.2.3) Place of performance

NUTS code: UKI

Main site or place of performance:

Please refer to Schedule 8 of the Framework Agreement.

#### II.2.4) Description of the procurement:

CM/PHR/16/5515/03 — 1.9.2019 to 31.8. 2020 – NHS Framework for the NHS London Region, Branded Medicines — Antiretrovirals with an option to extend (at the Authority's discretion) for a period or periods up to a total of 12 months.

Products associated with the lots are listed on Document No. 05 of the Invitation to offer.

Each individual National product code (NPC) pack description in each of the regions (London) is deemed to be a separate product for the application of the award criteria.

There is no restriction on the number of products that bidders can offer for, or be awarded.

The Framework Agreement is intended for use by the Department of Health, Public Health England and the NHS in England.

The framework may also be used by private sector contractors and agents working on behalf of the above.

#### II.2.5) Award criteria

Price is not the only award criterion and all criteria are stated only in the procurement documents

#### II.2.6) Estimated value

#### II.2.7) Duration of the contract, framework agreement or dynamic purchasing system

Start: 01/09/2019 End: 31/08/2020

This contract is subject to renewal: no

#### II.2.10) Information about variants

Variants will be accepted: yes

# II.2.11) Information about options

Options: no

#### II.2.12) Information about electronic catalogues

#### II.2.13) Information about European Union funds

The procurement is related to a project and/or programme financed by European Union funds: no

# **II.2.14)** Additional information

#### Section III: Legal, economic, financial and technical information

- III.1) Conditions for participation
- III.1.1) Suitability to pursue the professional activity, including requirements relating to enrolment on professional or trade registers
- III.1.2) Economic and financial standing

Selection criteria as stated in the procurement documents

III.1.3) Technical and professional ability

Selection criteria as stated in the procurement documents

- III.1.5) Information about reserved contracts
- III.2) Conditions related to the contract
- III.2.2) Contract performance conditions:
- III.2.3) Information about staff responsible for the performance of the contract

#### **Section IV: Procedure**

- IV.1) Description
- IV.1.1) Type of procedure

Open procedure

IV.1.3) Information about a framework agreement or a dynamic purchasing system

The procurement involves the establishment of a framework agreement Framework agreement with several operators

- IV.1.4) Information about reduction of the number of solutions or tenders during negotiation or dialogue
- IV.1.6) Information about electronic auction
- IV.1.8) Information about the Government Procurement Agreement (GPA)

The procurement is covered by the Government Procurement Agreement: yes

- IV.2) Administrative information
- IV.2.1) Previous publication concerning this procedure
- IV.2.2) Time limit for receipt of tenders or requests to participate

Date: 11/04/2019 Local time: 13:00

- IV.2.3) Estimated date of dispatch of invitations to tender or to participate to selected candidates
- IV.2.4) Languages in which tenders or requests to participate may be submitted:

**English** 

IV.2.6) Minimum time frame during which the tenderer must maintain the tender

Duration in months: 3 (from the date stated for receipt of tender)

IV.2.7) Conditions for opening of tenders

Date: 11/04/2019 Local time: 13:00

Place:

**Rutland House** 

Information about authorised persons and opening procedure:

Commercial medicines unit employee.

# Section VI: Complementary information

#### VI.1) Information about recurrence

This is a recurrent procurement: no

#### VI.2) Information about electronic workflows

Electronic ordering will be used Electronic invoicing will be accepted Electronic payment will be used

#### VI.3) Additional information:

Responding to this notice. Any supplier may be disqualified who does not respond to the following in the requisite manner:

1) Submission of expression of interest and procurement specific information. This procurement exercise will be conducted on the eTendering portal at: www.nhsengland.bravosolution.co.uk

Candidates wishing to be considered for this procurement exercise must register, and provide additional procurement specific information (if requested), through the eTendering portal as follows:

- 1.1) If not already registered, candidates should register on the eTendering portal at: https:// www.nhsengland.bravosolution.co.uk and click the link to register: accept the terms and conditions and click continue, enter your correct business and user details, note the username you chose and click save when complete, you will shortly receive an email with your unique password (please keep this secure);
- 1.2) Once registered, candidates must express interest as follows:
- (a) login to the eTendering portal;
- (b) select Response to ITT;
- (c) select ITTs open to all suppliers;
- (d) access listing related to this procurement NHS Framework Agreement for branded medicines London Tranche B and view details;
- (e) click on express interest button at the top of the page;
- (f) once you have expressed interest, the ITT will move to My ITTs, where you can download additional documentation (if required), and construct your reply as instructed. You must then publish your reply using the publish button.
- 1.3) For any support in registering on the portal or submitting your expression of interest please contact the eTendering Help-desk at +44 800 368 4850 or: help@bravosolution.co.uk
- 2) General supplier information. To manage and assess supplier information the Contracting Authority requests candidates provide their company profile in the

Governments supplier information database, sid4gov, as follows:

- 2.1) If not already registered, candidates must go to the following web page: https://sid4gov.cabinetoffice.gov.uk/ and select Register for sid4gov at the bottom of the page. Key in details as requested to search for your company. If you do not have a D-UN- S® Number, click on the link at the right of the page to obtain a number from D&B. candidates must obtain a Dun and Bradstreet (D&B) D-U-N-S® Number to enable registration on sid4gov.
- 2.2) Once registration is complete you are able to create and update your sid4gov company profile. Candidates should ensure all the mandatory fields of their sid4gov profile are completed and up to date for each procurement exercise. D&B data will be supplied automatically by D&B;
- 2.3) For further help or information concerning Sid4gov, please contact the sid4gov Helpdesk at: support@nqc.com or telephone +44 (0) 845 299 2994.

The Framework Agreement is for the benefit of other participating NHS bodies (whether acting individually, or on behalf of, or together as members of any consortia) along with any other non-NHS bodies which the participants deem necessary for the delivery of services or goods to NHS bodies, local authorities, other

Government departments or non-departmental public bodies charged with the delivery of healthcare or health related services.

Variants: an Offerer is permitted to submit any number of variants to the authority (subject to the minimum requirements set out in the ITO terms of offer Document 2, paragraph 8.2.1.

#### VI.4) Procedures for review

#### VI.4.1) Review body

The NHS Commissioning Board (Operating under the name of NHS England)

Runcorn

**United Kingdom** 

- VI.4.2) Body responsible for mediation procedures
- VI.4.3) Review procedure
- VI.4.4) Service from which information about the review procedure may be obtained
- VI.5) Date of dispatch of this notice:

07/03/2019